EC Number | Application | Comment | Organism |
---|---|---|---|
4.2.1.114 | drug development | the enzyme is a possible antifungal drug target | Cryptococcus neoformans var. grubii serotype A |
EC Number | Cloned (Comment) | Organism |
---|---|---|
4.2.1.114 | recombinant expression of GFP-tagged enzyme targeted to mitochondria | Cryptococcus neoformans var. grubii serotype A |
EC Number | Protein Variants | Comment | Organism |
---|---|---|---|
4.2.1.114 | additional information | generation of a CNAG_02565 deletion mutant, the deletion impairs mitochondrial functions, phenotype, overview | Cryptococcus neoformans var. grubii serotype A |
EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|---|
4.2.1.114 | mitochondrion | - |
Cryptococcus neoformans var. grubii serotype A | 5739 | - |
EC Number | Metals/Ions | Comment | Organism | Structure |
---|---|---|---|---|
4.2.1.114 | Fe2+ | required, in a Fe-S cluster | Cryptococcus neoformans var. grubii serotype A |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
4.2.1.114 | (R)-2-hydroxybutane-1,2,4-tricarboxylate | Cryptococcus neoformans var. grubii serotype A | - |
(Z)-but-1-ene-1,2,4-tricarboxylate + H2O | - |
? | |
4.2.1.114 | (R)-2-hydroxybutane-1,2,4-tricarboxylate | Cryptococcus neoformans var. grubii serotype A H99 / ATCC 208821 / CBS 10515 / FGSC 9487 | - |
(Z)-but-1-ene-1,2,4-tricarboxylate + H2O | - |
? | |
4.2.1.114 | (R)-2-hydroxybutane-1,2,4-tricarboxylate + H2O | Cryptococcus neoformans var. grubii serotype A | - |
(1R,2S)-1-hydroxybutane-1,2,4-tricarboxylate | - |
? | |
4.2.1.114 | (R)-2-hydroxybutane-1,2,4-tricarboxylate + H2O | Cryptococcus neoformans var. grubii serotype A H99 / ATCC 208821 / CBS 10515 / FGSC 9487 | - |
(1R,2S)-1-hydroxybutane-1,2,4-tricarboxylate | - |
? | |
4.2.1.114 | (Z)-but-1-ene-1,2,4-tricarboxylate + H2O | Cryptococcus neoformans var. grubii serotype A | - |
(1R,2S)-1-hydroxybutane-1,2,4-tricarboxylate | - |
? | |
4.2.1.114 | (Z)-but-1-ene-1,2,4-tricarboxylate + H2O | Cryptococcus neoformans var. grubii serotype A H99 / ATCC 208821 / CBS 10515 / FGSC 9487 | - |
(1R,2S)-1-hydroxybutane-1,2,4-tricarboxylate | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
4.2.1.36 | Cryptococcus neoformans var. grubii | - |
- |
- |
4.2.1.114 | Cryptococcus neoformans var. grubii serotype A | J9VIU5 | - |
- |
4.2.1.114 | Cryptococcus neoformans var. grubii serotype A H99 / ATCC 208821 / CBS 10515 / FGSC 9487 | J9VIU5 | - |
- |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
4.2.1.114 | (R)-2-hydroxybutane-1,2,4-tricarboxylate | - |
Cryptococcus neoformans var. grubii serotype A | (Z)-but-1-ene-1,2,4-tricarboxylate + H2O | - |
? | |
4.2.1.114 | (R)-2-hydroxybutane-1,2,4-tricarboxylate | - |
Cryptococcus neoformans var. grubii serotype A H99 / ATCC 208821 / CBS 10515 / FGSC 9487 | (Z)-but-1-ene-1,2,4-tricarboxylate + H2O | - |
? | |
4.2.1.114 | (R)-2-hydroxybutane-1,2,4-tricarboxylate + H2O | - |
Cryptococcus neoformans var. grubii serotype A | (1R,2S)-1-hydroxybutane-1,2,4-tricarboxylate | - |
? | |
4.2.1.114 | (R)-2-hydroxybutane-1,2,4-tricarboxylate + H2O | - |
Cryptococcus neoformans var. grubii serotype A H99 / ATCC 208821 / CBS 10515 / FGSC 9487 | (1R,2S)-1-hydroxybutane-1,2,4-tricarboxylate | - |
? | |
4.2.1.114 | (Z)-but-1-ene-1,2,4-tricarboxylate + H2O | - |
Cryptococcus neoformans var. grubii serotype A | (1R,2S)-1-hydroxybutane-1,2,4-tricarboxylate | - |
? | |
4.2.1.114 | (Z)-but-1-ene-1,2,4-tricarboxylate + H2O | - |
Cryptococcus neoformans var. grubii serotype A H99 / ATCC 208821 / CBS 10515 / FGSC 9487 | (1R,2S)-1-hydroxybutane-1,2,4-tricarboxylate | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
4.2.1.36 | LYS4 | - |
Cryptococcus neoformans var. grubii |
4.2.1.114 | CNAG_02565 | - |
Cryptococcus neoformans var. grubii serotype A |
4.2.1.114 | Homoaconitase | - |
Cryptococcus neoformans var. grubii serotype A |
4.2.1.114 | LYS4 | - |
Cryptococcus neoformans var. grubii serotype A |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
4.2.1.114 | Fe-S cluster | - |
Cryptococcus neoformans var. grubii serotype A |
EC Number | Organism | Comment | Expression |
---|---|---|---|
4.2.1.36 | Cryptococcus neoformans var. grubii | transcription factors HAP3 or HAPX negatively regulate expression of the gene, but only in iron-depleted conditions. The transcription factors do not influence LYS4 transcript levels upon iron repletion | down |
4.2.1.36 | Cryptococcus neoformans var. grubii | no LYS4 transcripts are observed in cells grown in low-iron medium, whereas abundant transcripts are observed in the cells grown in the high-iron medium. These results confirm the regulation of LYS4 by iron availability and indicate that the LYS4 gene is mainly transcribed when sufficient iron is present in the environment. Iron availability influences both transcript and protein levels for Lys4 | up |
4.2.1.114 | Cryptococcus neoformans var. grubii serotype A | the gene CNAG_02565 is significantly downregulated in the cfo1 mutant | down |
EC Number | General Information | Comment | Organism |
---|---|---|---|
4.2.1.36 | malfunction | deletion of the LYS4 gene results in lysine auxotrophy. The mutant shows increased sensitivity to oxidative stress, agents that challenge cell wall/membrane integrity, and azole antifungal drugs | Cryptococcus neoformans var. grubii |
4.2.1.36 | metabolism | the enzyme is involved in the lysine biosynthetic pathway | Cryptococcus neoformans var. grubii |
4.2.1.36 | physiological function | Lys4 plays an important role in mitochondrial iron metabolism, and is required for proper mitochondrial function in Cryptococcus neoformans. LYS4 is required for full virulence in Cryptococcus neoformans | Cryptococcus neoformans var. grubii |
4.2.1.114 | malfunction | deletion of the CNAG_02565 gene results in lysine auxotrophy. The lys4 mutant shows increased sensitivity to oxidative stress, agents that challenge cell wall/membrane integrity, and azole antifungal drugs. The phenotype is due in part to impaired mitochondrial function as a result of LYS4 deletion, which disrupts iron homeostasis in the organelle. The lys4 mutant is attenuated virulence in a mouse inhalation model of cryptococcosis. Loss of the enzyme results in organelle dysfunction due to a potential impact on Fe-S levels | Cryptococcus neoformans var. grubii serotype A |
4.2.1.114 | physiological function | the enzyme expression is regulated by iron levels and by the iron-related transcription factors Hap3 and HapX. The enzyme is essential for lysine biosynthesis and is required for full virulence. The iron metabolism and homeostasis have a large influence on the virulence of Cryptococcus neoformans | Cryptococcus neoformans var. grubii serotype A |